Federal regulators have posted two separate Class I actions involving the same family of hospital infusion pumps, the machines that push chemotherapy, antibiotics, IV fluids, blood products, and pain medication into patients at a controlled rate.
Neither action removes the pumps from hospitals. Both are corrections, meaning the devices stay in service and must be fixed or handled differently. The FDA applied its most serious recall classification to each, a designation reserved for problems that could cause serious injury or death if the device continues to be used without correction.
Both notices concern the Ivenix Large Volume Pump made by Fresenius Kabi, and the agency was explicit that the two issues are separate from each other and separate again from a software correction the agency posted in February.
A Drop You Cannot See Can Change How the Screen Behaves
The first correction covers pumps that have been dropped or severely jarred. According to the FDA notice, the touchscreen can start behaving unpredictably, registering random touches or failing to respond to a nurse's input at all. Testing traced the behavior to a touchscreen cable that works loose on impact.
The instruction to hospitals is unusually blunt. Pumps that have been dropped or severely jarred should be taken out of service immediately, "even if no damage is visible." Fresenius Kabi told customers in an April letter to remove such units from service, contact support, and follow a handling tip sheet until the instructions for use are formally updated.
An infusion pump that ignores a command or registers a phantom one can interrupt or delay therapy. As of May 6, the company had reported two serious injuries and no deaths linked to this issue.
A Battery Reading That Is Wrong in a Specific, Predictable Way
The second correction is a software problem in version 5.10.2, and it is the kind of flaw that only becomes dangerous when a patient leaves the room.
The FDA notice describes a software anomaly that can make the pump report a false battery health value, typically 69 percent, and then trigger a battery depletion alarm. If the pump is not reconnected to wall power, it shuts down within five minutes.
The agency's core instruction is that "units should be plugged in at all times instead of relying on battery power." Fresenius Kabi also told hospitals that any patient transport on an affected pump needs a plan for wall power access, and that a nurse should accompany patients receiving critical infusions or medications with short half-lives.
The company reported no serious injuries and no deaths tied to this issue as of April 30. A software update was expected in July, and the FDA notice does not indicate whether it has been distributed.
Where the Real Risk Concentrates
Neither of these problems poses the same level of risk to every patient on an IV.
A person receiving a bag of saline can absorb a brief pause. The patients the FDA notice singles out are the critically ill and those on medications with short half-lives, where the drug clears the body quickly, and an unplanned five-minute gap is not a rounding error. That category includes vasopressors that hold blood pressure up in an intensive care unit, certain sedatives, insulin infusions, and some cancer regimens where the delivery rate is part of the therapy.
Patient transport is the specific pinch point. The trip from an ICU bed to a CT scanner is exactly when a pump is unplugged, exactly when a false low battery alarm would fire, and exactly when finding an outlet in a hallway is hardest.
The Ivenix pump is indicated for adults, children, and newborns, and for delivery routes including intravenous, intra-arterial, epidural, and subcutaneous. It is used in hospitals and outpatient care settings, which means infusion centers and dialysis-adjacent settings are in scope alongside inpatient units.
A Pattern That Deserves Its Own Scrutiny
These two corrections did not arrive in isolation. The FDA posted an Ivenix software correction in February involving version 5.10.1 and earlier, tied to anomalies that could delay or interrupt infusions, with two serious injuries reported at that time. The agency also posted a removal in late 2025 for a lot of Ivenix administration sets assembled with the drip chamber and Luer lock in reversed positions, and a Class I recall in 2023 for mechanical interference in the pumps themselves.
Fresenius Kabi received an FDA warning letter in 2024 concerning the site where Ivenix devices were made, as reported by MedTech Dive. Taken together, that is a multi-year sequence of corrective actions on one product line, and it is a fair question for hospital procurement and biomedical engineering departments, not something patients can act on individually.
Reasonable Questions from a Hospital Bed
Patients and families cannot inspect a pump's software version, and they should not try. What they can reasonably do is notice and speak up.
If an infusion pump alarms repeatedly, if the screen appears to respond on its own, or if an infusion stops without explanation, tell the nurse rather than waiting for the next check. If a transport is planned while an infusion is running, it is reasonable to ask whether the pump will stay plugged in or run on battery, and whether a nurse is accompanying the trip.
Do not adjust, unplug, silence, or restart a pump yourself. Do not stop or change a prescribed infusion based on a news report. These are hospital-controlled devices, and the correction obligations fall on the facility.
Fresenius Kabi has told hospitals to post safety tip sheets in every area where affected pumps are stored and used, so the guidance may be visible on the unit. Clinicians and patients can report problems to the FDA through MedWatch. MedicalDaily will monitor both FDA notices for confirmation that the software update has shipped and for any change in reported injuries.
The newest confirmed facts are two separate Class I corrections on pumps that remain in use, with two serious injuries reported for the handling issue and none for the software issue. The patients most affected are the critically ill and those on short half-life medications, particularly during transport. The most reasonable action is to flag unusual pump behavior to nursing staff immediately. The central uncertainty is whether the promised software fix has reached every affected hospital.
Frequently Asked Questions
Are these pumps being taken out of hospitals? No. Both actions are corrections, which means the devices stay where they are used and must be fixed, updated, or handled differently. Individual pumps that have been dropped or severely jarred are supposed to be pulled from service.
Why is a correction still called the most serious recall type? The FDA classification reflects the potential consequence of continuing to use the device without the correction, not whether the product is physically removed.
What is the software problem? Version 5.10.2 can report a false battery health value, often 69 percent, then trigger a battery depletion alarm that shuts the pump down within five minutes unless it is reconnected to wall power.
Who is most at risk? The FDA notice identifies critically ill patients and those receiving medications with short half-lives, where a brief interruption matters most. Patient transport is the highest risk moment.
Has anyone been harmed? Fresenius Kabi reported two serious injuries and no deaths for the dropped or jarred pump issue as of May 6, and no serious injuries or deaths for the software issue as of April 30.
What should I do if I am on an IV pump right now? Tell your nurse if the pump alarms repeatedly, responds on its own, or stops unexpectedly. Ask whether a pump will stay plugged in during transport. Do not adjust or restart the device yourself.
Is this the same as the February recall? No. The FDA states that both July issues are separate from the February software correction, even though they affect the same devices.
